<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Intensity Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Intensity Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 13:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/intensity-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835842678dffbe2df0fcfd0.webp</url>
<title>Intensity Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation</guid>
<pubDate>Wed, 15 Apr 2026 13:15:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6</description>
</item>
<item>
<title>Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-2025-year-end-financial-results-and-highlights-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-2025-year-end-financial-results-and-highlights-and-provides-corporate-update</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the</description>
</item>
<item>
<title>Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-strengthens-ip-portfolio-with-issuance-of-new-patent-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-strengthens-ip-portfolio-with-issuance-of-new-patent-in-the-us</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>New US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-provides-update-on-the-phase-2-presurgical-triple-negative-breast-cancer-invincible-4-study-6</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-provides-update-on-the-phase-2-presurgical-triple-negative-breast-cancer-invincible-4-study-6</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of</description>
</item>
<item>
<title>Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-regains-compliance-with-nasdaqs-minimum-bid-price-requirement-24</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-regains-compliance-with-nasdaqs-minimum-bid-price-requirement-24</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology</description>
</item>
<item>
<title>Intensity Therapeutics Announces Reverse Stock Split</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-announces-reverse-stock-135800463</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-announces-reverse-stock-135800463</guid>
<pubDate>Fri, 13 Feb 2026 13:58:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that the board of directors of the Company approved a 1-for-25 reverse stock split (the "Reverse Split") of the Company's common stock. The Re</description>
</item>
<item>
<title>Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-highlights-2025-milestones-124700264</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-highlights-2025-milestones-124700264</guid>
<pubDate>Tue, 13 Jan 2026 12:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, today highlights key milestones achieved during 2025 and outlines strategic priorities for 2026.</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-present-two-124700779</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-present-two-124700779</guid>
<pubDate>Thu, 11 Dec 2025 12:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it will present two posters at the San Antonio Breast Cancer Symposium ("SABCS"), in San Antonio, TX being held at the Henry B. Gonzalez Conven</description>
</item>
<item>
<title>Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-granted-180-day-123000053</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-granted-180-day-123000053</guid>
<pubDate>Fri, 05 Dec 2025 12:30:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minim</description>
</item>
<item>
<title>Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-announces-two-presentations-124700230</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-announces-two-presentations-124700230</guid>
<pubDate>Thu, 04 Dec 2025 12:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, today announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), in San Antonio, TX on December 9-12, 2025.</description>
</item>
<item>
<title>Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-third-quarter-210200958</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-third-quarter-210200958</guid>
<pubDate>Thu, 06 Nov 2025 21:02:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces third quarter 2025 financial results and provides a corporate update.</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-pricing-120000471</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-pricing-120000471</guid>
<pubDate>Fri, 31 Oct 2025 12:00:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has entered into a securities purchase agreement with a new long-term fundamental investor for the purchase and sale of 5,000,000 shar</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-publication-113000609</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-publication-113000609</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces that eBioMedicine, a Lancet Discovery Science journal, has published the Company's phase 1/2 IT-01 clinical study manuscript for the treatment</description>
</item>
<item>
<title>Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-invincible-4-114700539</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-invincible-4-114700539</guid>
<pubDate>Wed, 10 Sep 2025 11:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provided an update on the INVINCIBLE-4 trial. A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, whe</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-participate-fireside-114700361</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-participate-fireside-114700361</guid>
<pubDate>Tue, 02 Sep 2025 11:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-regains-compliance-114700639</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-regains-compliance-114700639</guid>
<pubDate>Tue, 12 Aug 2025 11:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that the Company received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the St</description>
</item>
<item>
<title>Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-second-quarter-200600409</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-reports-second-quarter-200600409</guid>
<pubDate>Thu, 07 Aug 2025 20:06:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces second quarter 2025 financial results and provides a corporate update.</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-raises-6-114700705</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-raises-6-114700705</guid>
<pubDate>Mon, 04 Aug 2025 11:47:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that in July 2025 the Company added $6.6 million in gross proceeds ($6.3 million net) by selling 19,868,658 shares of its common stock via its At-th</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-int230-120000778</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-int230-120000778</guid>
<pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor ("MPNST"). In a study conducted in the Staedtke-Bai laboratory at Johns Hopkins Unive</description>
</item>
<item>
<title>Intensity Therapeutics, Inc. Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-pricing-034600031</link>
<guid isPermaLink="true">https://6ix.com/company/intensity-therapeutics-inc-common-stock/news/intensity-therapeutics-inc-announces-pricing-034600031</guid>
<pubDate>Thu, 12 Jun 2025 03:46:00 GMT</pubDate>
<description>Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its underwritten public offering of 6,675,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $2,002,500, before deducti</description>
</item>
</channel>
</rss>